Back to search

Netherlands· NL-3fcfcaaf0e25

Pombiliti 105mg, poeder voor concentraat voor oplossing voor injectie/infusie

A cipaglucosidase alfa product containing cipaglucosidase alfa, registered in Netherlands by Amicus Therapeutics Europe Limited. The same ATC class is registered in 13 of our 19 countries.

ATC A16AB23

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedPombiliti 105mg, poeder voor concentr…ATCA16AB23REGISTER NO.NL-3fcfcaaf0e25PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Cipaglucosidase alfa is registered in 13 of 19 countries.

Countries holding a registration under ATC A16AB23 (cipaglucosidase alfa), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose

Cipaglucosidase alfa · ATC A16AB23

13 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of cipaglucosidase alfa costs, country by country.

Normalised to the WHO defined daily dose (0.1 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Cipaglucosidase alfa · price per daily dose (0.1 g)

USD · FX 28 Sept 2026

  • CH Switzerland$1264.16
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
CIPAGLUCOSIDASE ALFA
Manufacturer
Amicus Therapeutics Europe Limited
Country
Netherlands (NL)
ATC code
A16AB23
ATC class
Cipaglucosidase alfa
Defined daily dose
0.1 g, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/22/1714

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/591cf064-20e8-4511-b43a-8f960f50d3af
GET /v1/drugs/591cf064-20e8-4511-b43a-8f960f50d3af?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder voor concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/pombiliti-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Cipaglucosidase Alfa",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp129217",
  "excipients": [
    "CITROENZUUR 1-WATER (E 330)",
    "MANNITOL (D-) (E 421)",
    "POLYSORBAAT 80 (E 433)",
    "STIKSTOF (HEAD SPACE) (E 941)",
    "TRINATRIUMCITRAAT 2-WATER (E 331)"
  ],
  "substances": [
    "CIPAGLUCOSIDASE ALFA"
  ],
  "leaflet_url": null,
  "authorised_at": "2023/03/20",
  "procedure_number": "EMEA/H/C/005703",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/22/1714",
  "additional_monitoring": "Y"
}

See everything about cipaglucosidase alfa.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.